DrugDashboards

Levothyroxine Sodium

Levothyroxine Sodium Anhydrous · LEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Sagent Pharmaceuticals

NDC 25021-0469-10 · 1 VIAL in 1 CARTON / 5 mL in 1 VIAL · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$190.35
Reported to Texas DSHS · 2026 annual filing · Sagent Pharmaceuticals

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MCG
$5.096
HCPCS J0650 · Jul 1, 2026 quarter · typically ASP + 6%

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA208749
TE code
AP
Approval date
Dec 21, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Levothyroxine Sodium Anhydrous (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCLEVOTHYROXINE SODIUM ANHYDROUS 500 ug/5mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCLEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 3, 2026
ENDO USA, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 2, 2026
ENDO USA, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 500 ug/5mLJul 15, 2026Sep 2, 2026
ENDO USA, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mLJul 15, 2026Sep 2, 2026
Fosun Pharma USA Inc.LEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCLEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mLJul 15, 2026Sep 2, 2026
MAIA Pharmaceuticals, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mLJul 15, 2026Sep 2, 2026
MAIA Pharmaceuticals, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 2, 2026
MAIA Pharmaceuticals, Inc.LEVOTHYROXINE SODIUM ANHYDROUS 500 ug/5mLJul 15, 2026Sep 2, 2026
Onesource Specialty Pharma LimitedLEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 2, 2026
Onesource Specialty Pharma LimitedLEVOTHYROXINE SODIUM ANHYDROUS 500 ug/5mLJul 15, 2026Sep 2, 2026
Onesource Specialty Pharma LimitedLEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsLEVOTHYROXINE SODIUM ANHYDROUS 200 ug/5mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsLEVOTHYROXINE SODIUM ANHYDROUS 100 ug/5mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsLEVOTHYROXINE SODIUM ANHYDROUS 500 ug/5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Levothyroxine Sodium — NDC 25021-0469-10," retrieved September 3, 2026, https://drugdashboards.com/drug/25021046910.

Free to cite with attribution — see how the data is put together.